Literature DB >> 11913677

Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences.

Gerald A Maguire1.   

Abstract

Antipsychotic agents differ in efficacy and side effects such as movement disorders and prolactin elevation because of varying mechanisms of action. A revised nomenclature for antipsychotic agents, which categorizes the drugs according to efficacy, risk of movement disorders, and risk of prolactin elevation, is described. Prolactin elevation, a potential side effect of some antipsychotic medications, is underdiagnosed but can have serious short-term and long-term consequences. Short-term problems include menstrual irregularities, sexual dysfunction, and depression. Long-term problems related to prolactin elevation include decreased bone density and osteoporosis, relapse of psychosis because of poor compliance due to sexual dysfunction or depression, and perhaps cancer, although more research in this area is needed. Despite the serious nature of these effects, prolactin elevation is seldom detected because clinicians often fail to inquire about sexual function or other symptoms that signal that a patient's prolactin may be elevated. These are problems that patients may not bring up with clinicians unless they are asked. Therefore, when patients are taking antipsychotic medications, clinicians should regularly inquire about sexual dysfunction, depression, menstrual disturbances, galactorrhea, and gynecomastia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11913677

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  24 in total

1.  Ziprasidone-induced galactorrhea in an adolescent female: a case report.

Authors:  Shakeel Raza; Fasiha Haq
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

2.  Hirsutism in a female adolescent induced by long-acting injectable risperidone: a case report.

Authors:  Ankit Patel; Naaz Malek; Fasiha Haq; Lauren Turnbow; Shakeel Raza
Journal:  Prim Care Companion CNS Disord       Date:  2013

3.  Antidepressant use and circulating prolactin levels.

Authors:  Katherine W Reeves; Olivia I Okereke; Jing Qian; Shelley S Tworoger; Megan S Rice; Susan E Hankinson
Journal:  Cancer Causes Control       Date:  2016-05-10       Impact factor: 2.506

Review 4.  First-episode schizophrenia: a focus on pharmacological treatment and safety considerations.

Authors:  Deanna L Kelly; Robert R Conley; William T Carpenter
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 5.  Adverse endocrine and metabolic effects of psychotropic drugs: selective clinical review.

Authors:  Chaya G Bhuvaneswar; Ross J Baldessarini; Veronica L Harsh; Jonathan E Alpert
Journal:  CNS Drugs       Date:  2009-12       Impact factor: 5.749

6.  Depression, Antidepressant Use, and Postmenopausal Breast Cancer Risk.

Authors:  Susan B Brown; Susan E Hankinson; Kathleen F Arcaro; Jing Qian; Katherine W Reeves
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-11-17       Impact factor: 4.254

Review 7.  Efficacy and safety of risperidone long-acting injection in elderly people with schizophrenia.

Authors:  Dhiren Singh; Daniel W O'Connor
Journal:  Clin Interv Aging       Date:  2009-09-01       Impact factor: 4.458

8.  Sexual problems in schizophrenia: prevalence and characteristics. A cross sectional survey.

Authors:  Ellen Wan-Yuk Harley; Jed Boardman; Tom Craig
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2009-08-23       Impact factor: 4.328

Review 9.  Drugs and prolactin.

Authors:  Mark E Molitch
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

10.  Teratogenicity and hyperprolactinemia.

Authors:  Chittaranjan Andrade
Journal:  Indian J Psychiatry       Date:  2009-01       Impact factor: 1.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.